Following graduation from the University of California at Berkeley and the Albert Einstein College of Medicine, Dr. Wu was a post-doctoral fellow and Lecturer in the Department of Zoology at the University of California at Berkeley. Prior to joining the federal government in 1979, he worked for a biotech company as a Senior Scientist for 5 years. In 1986 after working for 7 years in the Laboratory of Molecular Pharmacology of the NCI's intramural program, More…
The Clinical Grants and Contracts Branch (CGCB) manage a multidisciplinary research portfolio which includes translational research grants and cooperative agreements. The CGCB portfolio is concentrated in the areas of clinical oncology, surgical oncology and pharmacogenomics. These program areas are focused on the development of investigative clinical agents, related correlative studies, novel treatment regimens, and clinical and surgical methods development.
CGCB program staff participates in the planning, implementation and management of the Clinical Trials Cooperative Groups and other clinical consortia engaged in evaluating novel modalities for cancer treatment and management. CGCB program staff participates in extramural policy solicitation, formulation and budget development and assist with the management of the CTEP-sponsored clinical trials portfolio.
CGCB Program Directors (PDs) manage the scientific, technical, administrative and fiscal aspects of CTEP's extramural clinical research portfolio. PDs are responsible for, but are not limited to, the following activities:
ensuring that research project grants are scientifically and programmatically sound and technically appropriate
evaluating clinical research proposals for adherence to existing DCTD, NCI and NIH regulations and policies
reviewing the existing and pending grant portfolio to ensure a proper scientific balance, in addition to identifying and correcting areas with scientific gap and/or overlap
discovering and promoting new areas of scientific investigation and developing plans to exploit promising new therapeutic agents, modalities and treatment strategies
advising extramural investigators on funding opportunities, mechanisms, and grant application processes and promoting grantee interactions with other resources both internal and external to NCI
participating in NCI/NIH intramural/extramural working groups